BRAF and neoplasm: In contrast to BRAF inhibitors, mAbs partly exert their cytotoxic effects by reducing ectodomain density or by inducing receptor-mediated endocytosis through the activation of antibody-dependent cellular cytotoxicity (ADCC) toward tumor cells overexpressing the specific TAA [19,20,21].